When it comes to developing next-generation modalities like antibody-oligonucleotide conjugates (AOCs), the partners who are best positioned to advance these programs don’t fit the conventional CDMO model. Building an effective and manufacturable AOC demands specialized expertise, the kind that only comes from decades spent mastering the junction of bioconjugation and antibody design and development. While AOCs build on ADC bioconjugation, oligo payloads introduce a distinct set of challenges that reshape how chemistry, linker selection and analytical characterization must be approached. That's why selecting the right development partner at the start of a program is critical to an AOC’s success. Abzena , a leading global biologic and bioconjugates CRDMO, has spent over 25 years building that expertise, producing over 2,000 bioconjugates,1,400 linker-payloads and 400 ADCs in the process, an experience base that is unmatched. Its expertise in complex conjugates provides a deep scientific foundation for AOC development, where reproducible conjugation, analytical control and scalable processes are critical to moving candidates toward the clinic. “Because of that scientific trend and our legacy of being the go-to provider for developing complex conjugates, we have fast become the leader in AOC drug development,” says Geoffrey Glass, Chairman and CEO..

Life sciences organizations spend years developing breakthrough innovations, only to arrive in the market sounding remarkably similar to competing products. Scientific expertise may open the door, but in an increasingly competitive market, differentiation depends on communicating a clear commercial value that customers can recognize and understand. Inveniv has built its approach on helping life sciences organizations build that distinction. It approaches client engagements through a commercial lens, aligning marketing with sales and operational objectives rather than treating it as a standalone function. Organizations are supported from early-stage biotech and drug discovery through development, manufacturing and commercialization. .

At age 34, a woman from Minnesota learned she had metastatic colorectal cancer that spread to her liver. She subsequently underwent a living-donor liver transplant using a portion of her brother’s liver. Six months later, the disease appeared in her lungs. A Chicago surgeon agreed to perform a double lung transplant because she was young and otherwise healthy. Despite extensive clinical evaluation, the care team had limited biological insight into how aggressively her metastatic disease might behave. The estimated cost of her care approached $1.5 million, underscoring the extraordinary financial and clinical stakes of these decisions. Yet the likely behavior of her metastatic disease remained uncertain. Her experience illustrates the uncertainty clinicians may face when treatment decisions rely primarily on clinical and anatomical factors without a validated biological classification of the metastasis. Better biological stratification has the potential to improve patient selection for complex and costly interventions while helping avoid treatments unlikely to provide durable benefit. Metastatic disease accounts for approximately 90 percent of cancer-related deaths. Although clinicians have access to surgery, ablation, radiation and systemic therapies, determining which patients are most likely to experience durable outcomes following local intervention remains difficult. Traditional clinical and anatomical factors do not always capture the underlying biology of metastatic disease. For the Minnesota patient, each decision followed clinical criteria. None could read the tumor..

Custom antibody production remains a relationship-driven discipline in which scientific expertise must be matched with communication, trust, and a deep understanding of each researcher’s goals. At Pocono Rabbit Farm and Laboratory (PRF&L), that philosophy has shaped decades of work supporting universities, biotechnology companies, pharmaceutical organizations, and research institutions worldwide. The company’s story is reflected in the professional journey of Margaret Cleveland, Director of Antibody Production, whose growth within the organization mirrors PRF&L’s commitment to investing in its people. Margaret joined PRF&L in 2009 as a technician and gradually advanced through different roles before becoming Director of Antibody Production. Her experience provides a unique perspective on how technical knowledge, leadership development, and hands-on involvement contribute to successful research partnerships. Rather than viewing antibody production as a transactional service, she approaches each project as a collaborative effort between the laboratory team and the scientists who depend on its expertise..

A young boy’s sixth birthday was approaching, the day that he would become ineligible to receive a newly approved therapy for a rare genetic condition. Missing that deadline would have meant losing access to treatment. When his case reached Orsini, the team acted immediately, coordinating with the prescriber, family, payor, and manufacturer. Approvals were secured in record time, and the therapy was dispensed the day before his birthday, making him one of the first commercial patients in the U.S. to receive it. For Orsini, moments like these define the company’s purpose: speed, precision, and compassion when it matters most. Founded in 1987, Orsini has grown in recent years into a critical partner across the cell and gene therapy (CGT) ecosystem. The company’s approach is rooted in collaboration with patients, providers, biopharmaceutical innovators, and payors who share a common goal: to ensure that life-changing therapies reach the people who need them. At the heart of every process lies Orsini’s enduring promise: No Patient Left Behind. Every patient story at Orsini is personal. Blending precision with empathy, the company has guided over 6,800 patients and countless families, providers, and biopharma partners through the intricate pathways of cell and gene therapy, ensuring that care is as compassionate as it is exacting. Orsini provides the operational backbone for biopharmaceutical partners, turning therapy launches into coordinated successes. It delivers a streamlined pathway for healthcare providers by aiding with the benefit verification, reimbursement, and patient education processes. And for patients and families, it offers a steady hand—someone who understands that behind every form, signature, and vial is a life waiting for change..